Dechra Pharmaceuticals PLC/Osurnia business of Elanco Animal Health Incorporated Merger Inquiry

The CMA investigated and cleared the anticipated acquisition by Dechra Pharmaceuticals PLC of the Osurnia business of Elanco Animal Health Incorporated.

• From: Competition and Markets Authority
• Published: 26 March 2020
• Last updated: 15 July 2020 — See all updates

• Case type: Mergers
• Case state: Closed
• Market sector: Pharmaceuticals
• Outcome: Mergers - phase 1 clearance
• Opened: 26 March 2020
• Closed: 15 July 2020

Statutory timetable

Phase 1 date	Action
9 June 2020	Decision announced
20 April 2020	Launch of merger inquiry
26 March 2020 to 17 April 2020	Invitation to comment

Phase 1

CMA clearance decision

9 June 2020: The CMA has cleared the anticipated acquisition by Dechra Pharmaceuticals PLC of the Osurnia business of Elanco Animal Health Incorporated.

• Full text decision (15.7.20)

Launch of merger inquiry

20 April 2020: The CMA announced the launch of its merger inquiry by notice to the parties.

• Commencement of initial period notice (20.4.20)

Invitation to comment: Now closed

26 March 2020: The CMA is considering whether it is or may be the case that this transaction, if carried into effect, will result in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2002 and, if so, whether the creation of that situation may be expected to result in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services.

Contact

Please send written representations about any competition or public interest to [email protected].

Published 26 March 2020
Last updated 15 July 2020 + show all updates

1. 15 July 2020

   Full text decision published following the 9 June announcement that the CMA has cleared the anticipated acquisition.

2. 9 June 2020

   Clearance decision announced.

3. 20 April 2020

   Launch of merger inquiry announced.

4. 26 March 2020

   First published.